期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

去势抗拒前列腺癌治疗新药卡巴他赛 被引量：10

Cabizitaxel,a novel drug for castration-resistant prostate cancer
原文传递
导出
摘要 去势抗拒前列腺癌(CRPC)在一线多西他赛失败后缺乏有效的二线治疗手段,是近年来临床上面临的一个难题。卡巴他赛是一种新型半合成紫杉烷类化合物,临床前研究中对多西他赛敏感及不敏感的肿瘤模型均显示出广谱的抗肿瘤活性。III期临床研究显示,卡巴他赛较米托蒽醌显著提高多西他赛失败的CRPC的PSA和肿瘤客观缓解率,延长肿瘤进展时间和总生存时间。卡巴他赛最常见的不良反应为血液学毒性,最常见的非血液学毒性为腹泻。 （CRPC） remains gainst tumors that Failure of the first-line a challenge. Cabazitaxel, are sensitive or insensitive castration-resistant prostate cancer shows a broad antitumor activity a- to docetaxel. Phase III clinical trial revealed that cabazitaxel signifi- cantly improves the PSA and tumor response rate of CRPC, and prolongs the time to disease progression and overall survival time. The most common side effect is hematological toxicity and the most common nonhematological side effect is diarrhea
作者 周爱萍 房虹 李长岭 孙燕
机构地区 中国医学科学院北京协和医学院肿瘤医院
出处 《中国新药杂志》 CAS CSCD 北大核心 2013年第19期2229-2231,共3页 Chinese Journal of New Drugs
关键词 卡巴他赛 去势抗拒前列腺癌 药理学 药动学 cabazitaxel castratlon-resistant prostate cancer pharmacology pharmacokinetic
分类号 R979.1 [医药卫生—药品]
  • 相关文献

参考文献7

  • 1HWANG C. Overcoming docetaxel resistance in prostate cancer: a perspective review[J]. Ther Adv Med Oncol , 2012,4(6):329-340.
  • 2MITA AC, DENIS LJ, ROWINSKY EK, et al. Phase Ⅰ and phar- macokinetic study of XRP6258 (RPR 116258A) , a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors [ J 1. Clin Cancer Res ,2009,15 (2) :723 - 730.
  • 3PIVOT X, KORALEWSKI P, HIDALGO JL,et al. A muhicenter phase Ⅱ study of XRP6258 administered as a 1-h i. v. infusion ev- ery 3 weeks in taxane-resistant metastatic breast cancer patients [J]. Ann Oncol, 2008,19(9) :1547 - 1552.
  • 4DE BONO JS, OUDARD S, OZGUROGLU M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxe! treatment: a randomised open-label trial [ J ]. Lancet, 2010,376 ( 9747 ) : 1147 - 1154.
  • 5BECZE E. Manage side effects of cabazitaxel in patients with castrate- resistant prostate cancer[ J]. ONS Connect, 2012,27(9) :16 -17.
  • 6Cabazitaxet at 20 mg'm 2 compared to 25 mg'm 2 with predni- sone for the treatment of metastatic castration resistant prostate cancer(PROSELICA) [ EB/OL ]. http ://www. clinicahrials, gov/ et2/results? term = eabazitaxel&Search.
  • 7VILLANUEVA C, AWADA A, CAMPONE M,et al. A multicen- tre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer pro- gressing after anthracycline and taxane treatment: a phase Ⅰ/Ⅱ study[J]. Eur JCancer, 2011, 47(7) :1037-1045.

同被引文献103

  • 1单鸣秋,张发成,毛志英.多西他赛中有机溶剂残留量的毛细管气相色谱测定[J].中国医药工业杂志,2004,35(12):751-752. 被引量：2
  • 2秦立,胡昌勤,刘文英.顶空气相色谱法测定药品中残留溶剂的影响因素考察[J].药物分析杂志,2005,25(7):823-826. 被引量：40
  • 3叶定伟,李长岭.前列腺癌发病趋势的回顾和展望[J].中国癌症杂志,2007,17(3):177-180. 被引量：119
  • 4张伟中,张爱平,王权勇,等.一种卡巴他赛的制备方法:中国,102311410A[P].2012-01-11.
  • 5BOUCHARD H, BOURZAT JD, COMMERON A. Methods of treating cell lines expressing muhidrug resistance P-glycoprotein: US, 6372780 [ P]. 2002 - 04 - 06.
  • 6OUDARD S. TROPIC : phase III trial of cabazitaxel for the treat- ment of metastatic castration-resistant prostate cancer[ J]. Future Oncol,2011,7 (4) :497 - 506.
  • 7PETRYLAK DP, TANGEN CM, HUSSAIN MH, et al. Docetax- el and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer [ J ]. N Engl J Med, 2004,351 (15) :1513 - 1520.
  • 8BERRY DL, MO INPOUR CM, JIANG CS, et al. Quality of life and pain in advanced stage prostate cancer : results of a Southwest Oncology Group randomized trial comparing docetaxel and estra- mustine to mitoxantrone and prednisone [ J ]. J Clin Oncol, 2006, 24(18): 2828-2835.
  • 9MICHIELSEN DP, BRAECKMAN JG, DENIS L. Cabazitaxel for the treatment of prostate cancerI J]. Expert Opin Pharmaeother, 2001,12(6) :977 -982.
  • 10DIDIER E, ODDON G, PAUZE D, et al. Process for preparing derivatives of the taxoid family: US, 5962705[ P]. 1999-10-05.

引证文献10

二级引证文献21

中国新药杂志
2013年 第19期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部